Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Circ Cardiovasc Genet. 2014 Jul 16;7(4):434–443. doi: 10.1161/CIRCGENETICS.113.000448

Figure 2.

Figure 2

MYBPC3 protein level. A. Representative western blot and B. Graph summary of densitometric analysis for MYBPC3 protein normalized to GAPDH and expressed as a % of the average of controls run on each gel. Results are shown for control, non-failing hearts (N=10), and HCM hearts without sarcomere mutations (N=14), with MYBPC3 mutations (N=22), and with sarcomere mutations other than MYBPC3 (N=10). *P<0.001 for HCM with MYBPC3 mutations vs HCM with or without other sarcomere mutations, †P<0.05 for HCM without sarcomere mutations vs controls and for HCM with non-MYBPC3 sarcomere mutations vs controls.